Effects of SGLT2 Inhibitors on Diabetic Macular Edema

Effects of SGLT2 Inhibitors on Diabetic Macular Edema - Effects of SGLT2 Inhibitors on Diabetic Macular Edema

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000056634

Enrollment

1000

Registered

2025-01-06

Start date

2024-10-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Macular Edema

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Type 2 diabetes patients with no change in diabetes treatment for 4 weeks prior to screening test

Exclusion criteria

Exclusion criteria: Patients with iris neovascularization, vitreous hemorrhage, tractional retinal detachment, and active uveitis

Design outcomes

Primary

Measure	Time frame
Corrected visual acuity (logMAR conversion) and central retinal thickness by retinal optical coherence tomography in both eyes before and 4, 8, 12, 24, and 48 weeks after the start of SGLT2 inhibitor treatment.	—

Countries

Japan

Contacts

Public ContactHideyuki Oshima

Fukui University Ophthalmology

osm@u-fukui.ac.jp0776-61-8403

Outcome results